Today we look at how advanced therapeutic modalities (ATMs) are revolutionizing drug discovery, development and manufacturing, presenting both unparalleled opportunities and new challenges for businesses.

Drawing from their knowledge, our experts Alex Vadas, Adam Siebert and Jeff Holder unpack how new drug therapies such as engineered cell therapies, gene therapies and nucleic acid therapies are revolutionizing patient care and treatment options. They highlight the need for innovative business strategies to navigate complex manufacturing processes and supply chain logistics, the role of regulatory engagement, and the influence of artificial intelligence (AI) and machine learning in the realm of drug discovery.

Key points/topics covered:

• The transformative impact of new drug therapies on life sciences, requiring adaptations in business strategies
• The complexity of manufacturing for ATMs and its effect on the commercial viability of new treatments
• The importance of regulatory engagement in streamlining the drug development timeline for advanced therapies
• The intersection of AI and machine learning in expediting drug discovery for cell and gene therapies
• Manufacturing efficiency and supply chain consistency as a key differentiator in the outcomes and success rates of ATMs
  Interested in learning more? Read our Harvard Business Review article, A New Generation of Drug Therapies Requires New Business Strategies.

Connect with our experts on LinkedIn:
Alex Vadas, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/alexvadas/
Adam Siebert, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/adam-siebert-8772b327/
Jeff Holder, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/jeff-holder-ph-d-7a391087/

Visit L.E.K. Consulting at https://www.lek.com/

In today’s episode, we will focus on the influential trends and investment priorities shaping the specialty chemicals industry. Our subject matter experts will discuss the surge in innovation, digital transformation, and sustainability in the chemicals sector and highlight the strategic responses to recent industry challenges.

Key points/topics covered:

• Current investment trends and strategic priorities, such as innovation in alternative feedstocks and diversification in the specialty chemicals industry
• The implementation and impact of digital strategies, including operational efficiency and business growth, within chemical companies
• The significance of sustainability goals and consumer demand for sustainable products, which are driving specialty chemical manufacturers to innovate
• Actions taken by the chemical industry to promote more sustainable raw materials and leverage biosimilar opportunities and recycling
• Future directions for the chemicals industry, including addressing supply chain optimization and operational efficiency

To provide insights on these topics, you will hear from L.E.K. Consulting Managing Directors Carol Wingard, Peter Walter, Morgan Callahan and Amanda Davis Winters.

Interested in learning more? Read our Article, Key Issue Insights Into the Future of Specialty Chemicals.

Connect with our experts on LinkedIn:
Carol Wingard: https://www.linkedin.com/in/carolwingardlek/
Peter Walter: https://www.linkedin.com/in/peterwalterlek/
Morgan Callahan: https://www.linkedin.com/in/morganjcallahan/
Amanda Davis Winters: https://www.linkedin.com/in/adaviswinters/

Visit L.E.K. Consulting at https://www.lek.com/

In this episode of “Insight Exchange,” we explore the crucial role of Scope 3 emissions reduction in the pharmaceutical industry. Listen to L.E.K. Consulting experts Verena Ahnert and Max Cambras, who share their insights on the significance of Scope 3 emissions, the current state of commitments in pharma and how emissions reduction is both a strategic consideration and mutually beneficial to both pharma and the environment.

Key points/topics covered:

• Explanation of Scope 3 emissions and their importance in pharma

• The current state of Scope 3 commitments in the pharmaceutical industry

• Key drivers of Scope 3 emissions in pharma

• The strategic co-benefits of Scope 3 emissions reduction in the pharmaceutical industry

• The path to achieving strategic co-benefits through emissions reduction in pharma

Tune in for a deep dive into a pressing environmental issue that’s reshaping the pharma industry’s strategies and operations.

Interested in learning more? Read our Special Report, Scope 3 Emissions: A Strategic Imperative for Pharma Companies.

Connect with our experts on LinkedIn:
Verena Ahnert, Partner, L.E.K. Consulting: https://www.linkedin.com/in/verena-ahnert-7a449a2/
Max Cambras, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/max-cambras-08348411/

Visit L.E.K. Consulting at https://www.lek.com/